PP8 CHANGES OF EXCESS BODY WEIGHT IN CHILDREN WITH DYSLIPIDEMIAS ON LIPID-LOWERING DIETARY THERAPY DURING A TWO-YEAR FOLLOW-UP

Cardiovascular disease (CVD) is the first cause of morbility and mortality among adults. The relationship between dyslipidemias, childhood overweight and high risk of premature CVD is well known. Current guidelines about management of dyslipidemias in children and adolescents, recommended a prudent diet which maintained adequate nutrients and calories and ideal body weight, while reducing the proportion of intake from total fat, saturated fat and cholesterol intake. Because of its presumed safety, lipid-lowering dietary therapy has been considered as the miliarstone of management. The safety about nutritional status of the fat and cholesterol restricted diet was investigated in various clinical trials. Childhood overweight is defined by a value of BMI from 85th to 95th percentile, while a value of BMI > 95th percentile is used to define obesity. Excess Body Weight (EBW%) is considered as the percentage of weight exceeding 50th centile and is used to estimate the degree of overweight. Objective: To evaluate the relationship between EBW and dyslipidemia in a cohort of dislipidemic children. Materials and methods: During a period of twenty-eight months, from January 2008 to April 2010, 382 outpatients (188 m and 194 f), aged from 1 to 18 yrs, were recruited at our Paediatric Lipid Unit. 246/382 were affected by familial hypercholesterolemia (FH), 9/382 by secondary hypercholesterolemia (SH), 3/382 by primary hypertrygliceridemia (PHT), 8/382 by secondary hypertrygliceridemia (SHT) and 116/382 hadn’t yet received a defined diagnosis. During this period of follow-up we estimated the EBW of our patients at the first visit, when children were in free diet. After they started a dietary program was evaluated the trend of weight at each control through analysis of EBW. Results: The mean value of EBW decreases from 111% (at the first visit) to 101,33% (at the last control) in patients with FH, from 126% to 111% in patients with SH, from 105,46% to 95,1% in patients with PHT, from 158,53% to 130,8% in patients with SHT while eraised from 112,98% to 129,21% in patients without a defined diagnosis. The graph below shows the trend of EBW for each group of patients.